Genomic tests using next-generation sequencing (NGS) technologies are increasingly being offered in a range of clinical settings. However, tests based on NGS may only transform clinical practice if patients and clinicians have access to them. This requires both favorable coverage decisions by public and private payers (eg, Medicare, Medicaid, commercial insurers) and adequate reimbursement levels to reward the development of innovative tests. Given that the hallmark of NGS technologies is the production of large amounts of data that require a bioinformatics infrastructure, sophisticated computational tools, and professional interpretation of the results, the current reimbursement and coding environment is not structured to necessarily recognize the value of NGS tests.
Deverka PA, Kaufman D, McGuire AL. Overcoming the Reimbursement Barriers for Clinical Sequencing. JAMA. 2014;312(18):1857-1858. doi:10.1001/jama.2014.14915